The hypoxic microenvironment of tumours, acting via hypoxia inducible factor 1α (HIF-1α), might promote the angiogenic stimulation required for cancer development, with a resultant aggressive cell pheno type and rapid malignant progression. 1 In their recent article, Marignol et al.
2 described the importance of notch signalling pathways in differentiation, prolifer ation, angiogenesis, vascular remodel ling and apoptosis in prostate cancer (Marignol, L., Rivera-Figueroa, K., Lynch, T. & Hollywood, D. Hypoxia, notch signalling, and prostate cancer. Nat. Rev. Urol. 10, 405-413; 2013). The Review highlighted similarities between notch-activated and hypoxic prostate cancer cells. We believe that normoxic HIF-1α expression in pros-α expression in prosexpression in prostate cancer, is equally important to-if not more important than-hypoxia mediated by HIF-1α. Indeed, a better understanding of the former would lead to improved prognostication and, potentially, reduced treatment resistance in men with this disease.
Although HIF-1α has a key role in the physio logical response to hypoxia, its importance in cancers is less clear. High expression of HIF-1α in some cancer cell lines (for example, renal and breast cancers) has been shown to increase angiogenesis and cancer cell survival, whereas in other cancers (such as ovarian carcinoma), high HIF-1α concentrations contribute to increased apoptosis. 3 In prostate cancer, HIF-1α overexpression has been linked with shorter time to biochemical recurrence in patients receiving radiotherapy or surgery, castration resistance, chemo resistance and metastasis.
4-6 Although hypoxia is a strong driver of HIF-1α expression, and the presence of hypoxic regions has been shown in many human tumours, the localized expression of HIF-1α and its down-α and its downand its downstream targets only in the hypoxic areas of tumours has been difficult to demon strate. 7 Furthermore, it has been consistently difficult to demonstrate localized hypoxia, particularly in high-grade prostate cancer; consequently, HIF-1α expression is thought to be independent of hypoxia. 9 Several differ ent hypotheses, including gene amplifi cation, 10 increased transcription of HIF-1α mRNA, 11 single nucleotide poly morphisms 12 and expression of truncated HIF-1α isoforms 13 have been proposed to explain the overexpression of HIF-1α in prostate cancer tumours and cell lines under normoxic conditions. However, as yet no definitive consensus can explain the mechanisms involved.
In addition to the widely accepted mecha nism of hypoxia-induced posttranslational stabilization of HIF-1α by decreased degradation, current evidence suggests that the hypoxia-independent normoxic upregulation of HIF-1α expres-α expres-expression can occur by increased translation. In prostate cancer cell lines, overexpression of HIF-1α protein under normoxic conditions is probably attributable to the increased efficiency of translation of the corresponding mRNA, 6 which might be mediated by the PI3K/Akt/mTOR pathway.
14 Whether the increased translation of HIF-1α occurs via cap-dependent or cap-independent pathways remains to be determined. Thus, understanding which of these translation mechanisms leads to upregulation HIF-1α overexpression in normoxia could lead to future targeted therapy for prostate cancer.
As HIF-1α has a central role in the acti-α has a central role in the actihas a central role in the activation of numerous pathways responsible for tumour progression, it has become an a ttractive target for cancer therapy. Various different types of inhibitors have been developed, including inhibitors of HIF-1α dimerization, HIF-1α DNA binding, HIF-1α transcription, small molecules that affect the HIF-1α protein level and natural product-based inhibitors. 15 HIF-1α regulates many normal physiological processes and an agent that inhibits HIF-1α might prevent normal cells from responding to a situation (such as hypoxia) that might be associated with toxicity. Thus, we believe that a better understanding of the normoxic regulation of HIF-1α in prostate cancer cells could direct the discovery of specific HIF-1α inhibitors that could then potentially lead to therapies better targeted against treatment resistance, and will provide better outcomes for men with prostate cancer.
